Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced today that it will disclose its second quarter 2025 financial results following market close on August 5, 2025. In conjunction with this announcement, Rigel's senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). The call will provide insights into the company's financial performance and an update on its ongoing business operations.

Participants interested in joining the conference call can do so by dialing the domestic number 877-407-3088 or the international number 201-389-0927. Additionally, the company’s website will feature a live webcast of the call along with accompanying presentation slides. For those unable to attend the live event, the webcast will be archived and available for replay for a duration of 90 days.

Rigel Pharmaceuticals, founded in 1996 and headquartered in South San Francisco, California, focuses on discovering and developing novel therapies aimed at improving the quality of life for patients suffering from hematologic disorders and cancer. The company aims to provide significant advancements in treatment options through its innovative research and product pipeline.

For further inquiries, investors can reach out to Rigel Pharmaceuticals directly at 650-624-1232 or via email at ir@rigel.com. Media inquiries can be directed to David Rosen at Argot Partners by phone at 646-461-6387 or via email at david.rosen@argotpartners.com.

Investors and interested parties are encouraged to learn more about Rigel and its developments by visiting the company’s website at www.rigel.com.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is set to release its second quarter 2025 financial results on August 5, 2025, following which senior management will provide a comprehensive business update. This upcoming announcement marks a critical moment for investors and stakeholders, as it will not only reflect the company's financial health but also offer insights into its strategic direction and market performance.

Investors should prepare for potential volatility in Rigel's stock price in the days leading up to and following this announcement. Historically, biotech stocks can react significantly to earnings reports, particularly when investors are keenly focused on product pipeline developments, clinical trial progress, and any potential partnerships or collaborations that could influence Rigel's revenue streams.

Key areas to watch during the conference call will include updates on Rigel’s product pipeline, specifically any advancements in therapies targeting hematologic disorders and cancers. Investors will be particularly attentive to how recent clinical trial results have fueled or inhibited future growth projections. Additionally, any commentary around regulatory pathways or anticipated approval timelines could serve as critical indicators for the stock's performance moving forward.

In terms of financial expectations, analysts will likely focus on revenue growth, R&D expenditures, and market forecasts. Paying close attention to management's guidance for the remainder of 2025 can provide valuable insight into the company's operational trajectory.

Overall, while Rigel has demonstrated commitment to innovation within the biotech space, investors should remain cautious and weigh both the potential opportunities presented by new therapies against the inherent risks associated with biotech investments, especially given the sector's volatility. Monitoring post-call market reactions and analyst ratings will be essential for making informed investment decisions.